Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Gilead Sciences stock nears its all-time high
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Gilead Sciences stock nears its all-time high: buy or sell?
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million settlement with American authorities. It has risen for two consecutive weeks,
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.
Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 5.7% Return On Equity?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would
Why Gilead Sciences Stock Thrashed the Market Today
There was some good news in the clinical sphere for Gilead Sciences ( GILD 2.74%) on Thursday, and this drove its stock price up by almost 3% that trading session. A late-stage clinical trial of an investigational drug yielded encouraging initial results, hence the rise. In comparison, the S&P 500 index inched up by 0.8% on the day.
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 5,634.58 and the Dow Jones Industrial Average DJIA falling 0.04% to 41,606.18.
FiercePharma
18m
Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M deal
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
securingindustry.com
2h
Gilead chalks up another win in fake HIV meds lawsuit
Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.
BioSpace
7d
Gilead Touts 96% HIV Risk Reduction With Twice-Yearly PrEP, Eyes Regulatory Filings
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
FiercePharma
19h
Gilead's Kite exits China cell therapy joint venture with Fosun Pharma
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
4d
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
2d
Health activists object to patent filed by US firm Gilead Sciences on anti-HIV drug
The Mumbai-based non-government entity called Sankalp Rehabilitation Trust, which works with HIV-positive people, had opposed ...
GlobalData on MSN
4d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
Zacks.com on MSN
6d
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
Gilead Sciences, Inc. GILD announced upbeat results from an interim analysis of a second late-stage study evaluating the use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
India
HIV
Yuhan
lenacapavir
Feedback